NCT05998863View on ClinicalTrials.gov

EffCaMgCit to Prevent Mineral Metabolism and Renal Complications of Chronic PPI Therapy

PHASE3RecruitingINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

April 19, 2024

Primary Completion Date

September 30, 2026

Study Completion Date

December 31, 2026

Conditions
OsteoporosisHypomagnesemia
Interventions
DRUG

EffCaMgCit

Each sachet of EffCaMgCit will contain 19 meq or 380 mg calcium, 10 meq (122 mg) magnesium, and 50 meq total citrate.

OTHER

Placebo

Each sachet of Placebo will contain microcrystalline cellulose, but no calcium, magnesium or citrate.

Trial Locations (2)

75390

RECRUITING

UT Southwestern Medical Center, Dallas

75390-9107

RECRUITING

University of Texas Southwestern Medical Center, Dallas

All Listed Sponsors
lead

University of Texas Southwestern Medical Center

OTHER